Flavan-3-ols consumption and cancer risk: a meta-analysis of epidemiologic studies

Lei Lei; Ying Yang; Hongiuan He; Erfei Chen; Le Du; Jing Dong; Jin Yang

doi:10.18632/oncotarget.12017

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Flavan-3-ols consumption and cancer risk: a meta-analysis of epidemiologic studies

Lei Lei, Ying Yang, Hongiuan He, Erfei Chen, Le Du, Jing Dong and Jin Yang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:73573-73592. https://doi.org/10.18632/oncotarget.12017

Metrics: PDF 2170 views | HTML 4278 views | ?

Abstract

Lei Lei1,2, Ying Yang1,2, Hongjuan He1,2, Erfei Chen1,2, Le Du1,2, Jing Dong1,2, Jin Yang1,2

1Key Laboratory of Resources Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi’an 710069, China

2Institute of Preventive Genomic Medicine, Xi’an 710069, China

Correspondence to:

Jin Yang, email: [email protected]

Keywords: meta-analysis, flavan-3-ols, cancer, colorectal cancer, breast cancer

Received: March 29, 2016 Accepted: July 27, 2016 Published: September 14, 2016

ABSTRACT

Although numerous in vitro studies and animal model data have suggested that flavan-3-ols, the most common subclass of flavonoids in the diet, may exert protective effects against cancer, epidemiologic studies have reported inconclusive results for the association between flavan-3-ols intake and cancer risk. Therefore, we conducted this meta-analysis of epidemiologic studies to investigate the preventive effects of flavan-3-ols on various types of cancers. A total of 43 epidemiologic studies, consisting of 25 case-control and 18 prospective cohort studies, were included. A significant inverse association was shown between flavan-3-ols intake and the risk of overall cancer (relative risk (RR) 0.935, 95%CI: 0.891-0.981). When cancer types were separately analyzed, a statistically significant protective effect of flavan-3-ols consumption was observed in rectal cancer (RR 0.838, 95%CI: 0.733-0.958), oropharyngeal and laryngeal cancer (RR 0.759, 95%CI: 0.581-0.993), breast (RR 0.885, 95%CI: 0.790-0.991) in case-control studies and stomach cancer in women (RR 0.633, 95%CI: 0.468-0.858). Our analysis indicates the potential benefits of flavan-3-ols in cancer prevention.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12017

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Flavan-3-ols consumption and cancer risk: a meta-analysis of epidemiologic studies

Abstract